<DOC>
	<DOCNO>NCT01000974</DOCNO>
	<brief_summary>The purpose study evaluate safety , demonstrate lot-to-lot consistency vaccine , address relevant concomitant vaccine administration provide comparison GSK Biologicals ' Hib conjugate vaccine license monovalent Hib vaccine ActHIB well license combination product Pentacel infants 2 , 4 , 6 15-18 month age . This study design primary booster phase .</brief_summary>
	<brief_title>Consistency &amp; Immunogenicity Study 3 Lots GSK 's Hib Conjugate Vaccine Versus ActHIB &amp; Pentacel Healthy Infants</brief_title>
	<detailed_description>This protocol post update follow protocol amendment 3 , date 12 April 2011 . The impacted section : Eligibility Criteria ( Exclusion criterion ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR [ ] ) comply requirement protocol ( e.g. , completion diary card , return followup visit ) . A male female , include , 6 12 week age time first vaccination . Written inform consent obtain subject 's parent/LAR . Healthy subject establish medical history clinical examination enter study . Born gestation period minimum 36 week . Infants receive previous dose hepatitis B vaccine receive 1 dose hepatitis B vaccine administer least 30 day prior enrollment . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Planned administration vaccine foreseen study protocol within 30 day first dose study vaccine 30 day booster dose . Previous vaccination Haemophilus influenzae type b , diphtheria , tetanus , pertussis , Pneumococcus , rotavirus and/or poliovirus ; one previous dose hepatitis B vaccine . History Haemophilus influenzae type b , diphtheria , tetanus , pertussis , pneumococcal , rotavirus , poliovirus , hepatitis B disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine , include dry natural latex rubber . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . All vaccine administer person minor illness . Administration immunoglobulins and/or blood product since birth plan administration study period . Concurrent participation another clinical study , 30 day prior study entry time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Child care . History intussusception . History uncorrected congenital malformation gastrointestinal tract would predispose infant intussusception . History Severe Combined Immunodeficiency Disease .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>booster vaccination</keyword>
	<keyword>Gram-negative bacterial infection</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>vaccine , conjugate</keyword>
	<keyword>primary vaccination course</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>safety</keyword>
	<keyword>infant , child</keyword>
</DOC>